Name | Number of supported studies | Average coverage | |
---|---|---|---|
pericyte | 28 studies | 37% ± 20% | |
oligodendrocyte precursor cell | 15 studies | 79% ± 14% | |
fibroblast | 14 studies | 25% ± 14% | |
smooth muscle cell | 13 studies | 32% ± 18% | |
endothelial cell | 10 studies | 30% ± 12% | |
astrocyte | 9 studies | 28% ± 16% | |
type I pneumocyte | 8 studies | 48% ± 14% | |
basal cell | 8 studies | 29% ± 13% | |
oligodendrocyte | 8 studies | 31% ± 16% | |
epithelial cell | 6 studies | 27% ± 12% | |
retina horizontal cell | 6 studies | 65% ± 14% | |
Mueller cell | 6 studies | 35% ± 22% | |
GABAergic neuron | 5 studies | 41% ± 13% | |
interneuron | 5 studies | 37% ± 12% | |
cardiac muscle cell | 5 studies | 43% ± 12% | |
connective tissue cell | 5 studies | 34% ± 19% | |
glutamatergic neuron | 4 studies | 29% ± 9% | |
myofibroblast cell | 4 studies | 22% ± 10% | |
differentiation-committed oligodendrocyte precursor | 3 studies | 70% ± 11% | |
transit amplifying cell | 3 studies | 31% ± 17% | |
mesothelial cell | 3 studies | 50% ± 17% | |
podocyte | 3 studies | 87% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 95% | 1854.58 | 2507 / 2642 | 99% | 44.05 | 696 / 705 |
kidney | 100% | 3423.74 | 89 / 89 | 89% | 20.33 | 805 / 901 |
skin | 98% | 1934.45 | 1770 / 1809 | 82% | 27.31 | 389 / 472 |
bladder | 100% | 2327.62 | 21 / 21 | 77% | 21.92 | 388 / 504 |
breast | 98% | 2562.99 | 451 / 459 | 77% | 11.60 | 861 / 1118 |
intestine | 85% | 1288.90 | 821 / 966 | 79% | 12.54 | 418 / 527 |
pancreas | 86% | 611.46 | 282 / 328 | 74% | 11.40 | 132 / 178 |
lung | 100% | 2938.36 | 578 / 578 | 47% | 6.56 | 545 / 1155 |
uterus | 100% | 2447.80 | 170 / 170 | 44% | 8.90 | 200 / 459 |
esophagus | 84% | 807.63 | 1209 / 1445 | 55% | 5.72 | 100 / 183 |
thymus | 96% | 974.93 | 629 / 653 | 40% | 3.22 | 242 / 605 |
prostate | 98% | 1151.44 | 239 / 245 | 32% | 2.42 | 159 / 502 |
stomach | 48% | 280.99 | 171 / 359 | 77% | 11.89 | 219 / 286 |
ovary | 69% | 515.99 | 125 / 180 | 38% | 3.38 | 164 / 430 |
ureter | 0% | 0 | 0 / 0 | 100% | 41.75 | 1 / 1 |
adipose | 98% | 1941.11 | 1182 / 1204 | 0% | 0 | 0 / 0 |
liver | 65% | 468.77 | 148 / 226 | 32% | 2.74 | 131 / 406 |
heart | 95% | 1854.61 | 820 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 95% | 1444.40 | 1262 / 1335 | 0% | 0 | 0 / 0 |
spleen | 94% | 1038.43 | 227 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 64% | 10.33 | 29 / 45 |
adrenal gland | 26% | 166.16 | 67 / 258 | 28% | 2.47 | 64 / 230 |
eye | 0% | 0 | 0 / 0 | 50% | 5.73 | 40 / 80 |
muscle | 21% | 111.24 | 166 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 17% | 0.97 | 5 / 29 |
peripheral blood | 1% | 5.42 | 7 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_2000352 | Biological process | negative regulation of endothelial cell apoptotic process |
GO_0001755 | Biological process | neural crest cell migration |
GO_0090263 | Biological process | positive regulation of canonical Wnt signaling pathway |
GO_0045766 | Biological process | positive regulation of angiogenesis |
GO_0050918 | Biological process | positive chemotaxis |
GO_0007162 | Biological process | negative regulation of cell adhesion |
GO_0021536 | Biological process | diencephalon development |
GO_0007155 | Biological process | cell adhesion |
GO_1990256 | Biological process | signal clustering |
GO_0007267 | Biological process | cell-cell signaling |
GO_0050919 | Biological process | negative chemotaxis |
GO_0007413 | Biological process | axonal fasciculation |
GO_0002043 | Biological process | blood vessel endothelial cell proliferation involved in sprouting angiogenesis |
GO_0030335 | Biological process | positive regulation of cell migration |
GO_0001938 | Biological process | positive regulation of endothelial cell proliferation |
GO_2001028 | Biological process | positive regulation of endothelial cell chemotaxis |
GO_0048675 | Biological process | axon extension |
GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0030836 | Biological process | positive regulation of actin filament depolymerization |
GO_0071526 | Biological process | semaphorin-plexin signaling pathway |
GO_0048842 | Biological process | positive regulation of axon extension involved in axon guidance |
GO_0007399 | Biological process | nervous system development |
GO_0060326 | Biological process | cell chemotaxis |
GO_0007411 | Biological process | axon guidance |
GO_0048843 | Biological process | negative regulation of axon extension involved in axon guidance |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0035373 | Molecular function | chondroitin sulfate proteoglycan binding |
GO_0030215 | Molecular function | semaphorin receptor binding |
GO_0045545 | Molecular function | syndecan binding |
GO_0043395 | Molecular function | heparan sulfate proteoglycan binding |
GO_0045499 | Molecular function | chemorepellent activity |
Gene name | SEMA5A |
Protein name | Semaphorin 5A isoform B Semaphorin-5A (Semaphorin-F) (Sema F) Semaphorin 5A isoform A Semaphorin 5A |
Synonyms | SEMAF |
Description | FUNCTION: Bifunctional axonal guidance cue regulated by sulfated proteoglycans; attractive effects result from interactions with heparan sulfate proteoglycans (HSPGs), while the inhibitory effects depend on interactions with chondroitin sulfate proteoglycans (CSPGs) (By similarity). Ligand for receptor PLXNB3. In glioma cells, SEMA5A stimulation of PLXNB3 results in the disassembly of F-actin stress fibers, disruption of focal adhesions and cellular collapse as well as inhibition of cell migration and invasion through ARHGDIA-mediated inactivation of RAC1. May promote angiogenesis by increasing endothelial cell proliferation and migration and inhibiting apoptosis. . |
Accessions | Q13591 X5DR95 ENST00000652226.1 ENST00000382496.10 ENST00000513968.4 D6RAF4 X5DPA6 |